Summary. The aim of this study was to investigate the influence of glibenclamide on insulin release via insulinotropic gut factors and via a direct action on the pancreas. Maximum peripheral IRI levels appeared 1 minute after intragastric administration of the minimal effective dose of glibenclamide to rats. The corresponding drug levels were high (600 ng/g) in the duodenal mucosa, but low (2 ng/ml) in the peripheral serum. These concentrations were too low to cause insulin release by direct action on the pancreas. Intragastric glibenclamide increased the amount of "duodenal insulin releasing activity" (DIP, A) in the mucosa immediately after drug administration. When glibenclamide was dissolved in plasma at a high concentration (1 ~g/ml) and then injected into the coeliac trunk of an in-situ rat pancreas preparation, no additional effect on portal IRI levels was measured as compared with injection of serum alone. In contrast significant IRI release was noticed when glibenclamide was dissolved in serum (1 ~g/ml) of rats pretreated with the drug intragastrically. The plasma of pretreated rats without addition of glibenclamide was ineffective. The results suggest that glibenclamide may have two effects, one releasing insulin at the pancreas directly, and the other inducing the release of a gastrointestinal factor which amplifies the first effect. Neither glibenclamide nor the factor alone can provoke an IRI release under physiological conditions. The possible importance of these findings for the regulation of insulin secretion is discussed.
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It is generally accepted that the blood glucose lowering sulfonylureas promote their insulinotropic effects by acting directly on the pancreas. However, several points remain unexplained. There is a contradiction between drug pharmacokinetics and pharmacodynamics of glibenclamide [1, 16] . After intragastric and i.v. administration of this drug the maximal concentrations of IRI were independent of the route of administration. The corresponding peripheral blood levels of the drug, however, were much lower after oral administration. Furthermore it has been found that the antidiabetic action of glibenclamide is still present after three times the ts0 of its elimination from the blood, when levels have become very low (< 40 ng/ml) [25, 1] .
In 1969 a dual mode of action of glibenclamide was suggested [16] , one via the release of gastrointestinal mediators, effective in releasing insulin, the other by direct induction of insulin release at the pancreas.
A study was carried out to investigate the effect of gastrointestinal mediators in the insulinotropic action of glibenclamide.
Material and Methods
Male SPF Wistar rats, weighing about 300 g, were used, and unless otherwise stated were fasted overnight. When fed rats were used the animals had free access to Altromin | Glibenclamide was labelled with tritium in 1-position of the cyclohexyl ring by catalytic exchange, yielding a specific radioactivity of 1.9 Ci/g. The material contained less than 1% radioactive contamination, and no exchange of label could be seen during short-term (2 hours) experiments in rats. The labelled glibenclamide was dissolved as sodium salt in saline at a concentration of 20 gg/ml. w. Heptner et al.: Extrapancreafic and Pancreatic Actions of Glibenclamide 0.2 mg/kg of the soiubilized drug was administered intragastrically by a stomach tube. This was the minimum effective dose in this species [2] . Fasted animals were used for the kinetic studies in order to avoid variation of the results caused by different stomach content. The rats were sacrificed by decapitation at the times indicated in the figures. Heparinized plasma was prepared from the blood. The small intestine was removed in toto and rinsed with 20 ml saline. Radioactivity was measured in the washing solution for glibenclamide determination. Samples of duodenal mucosa and liver were taken, homogenized in water and radioactivity was measured in an aliquot as described below.
The method used in another series of experiments is characterized by a system of donor and receptor rats [31] previously described. In brief: in the first subseries the donor rats were treated with the minimum effective dose of glibenclamide (0.2 mg/kg) intragastrically. In this experiment animals had free access to food to enhance insulin release in vivo. At the times indicated in figure 4 the animals were sacrificed by decapitation. Blood was collected for IRI determination in heparinized plasma. After laparatomy the duodenum was rapidly excised between the pylorus and the pancreaticobiliary duct. After rinsing the duodenum with 20 ml saline (4 ~ the mucosa was scraped off, weighed and homogenized in cold saline (100 mg/ml), with a Potter homogeniser. The time between sacrifice and homogenisation was constant at 2 minutes. After centrifugation (3500 g, 30 min) the supernatant was collected and stored at -20 ~ tmtil used for determination of DIRA in the receptor rat.
The receptor rats were fasted 24 hours and anaesthetised with intraperitoneal pentobarbital (25 mg/kg body weight). After laparatomy the coeliac trunk was prepared for injection of the extracts and a catheter was inserted into the portal vein. Ten min later 0.7 ml of blood was collected for basal measurements. 0.2 ml of the extracts was injected into the coeliac trunk within about 10 seconds. 1 min, 5 min, 10 rain, and 15 min after extract injection, 0.7 ml portal blood was taken for IRI determination. In addition to the results of figure 4, controls containing 0.5 ~tg glibenclamide per ml extract of duodenal mucosa were tested. The experimental modifications of the other subseries are schematically described in figure 5 .
IRI was determined in the portal blood of receptor rats by a double antibody radioimmunoassay [14] using rat insulin standard (Novo, batch no R 171). Radioactivity measurements of 3H-glibenclamide were performed by liquid scintillation counting after combustion of fluids and homogenates of tissues in an automatic sample oxidizer.
Results were presented as mean ___ SEM. For statistical comparison the t-test for paired differences was used.
Results
Maximal IRI levels in peripheral blood occurred one minute after both intragastric and i.v. administration, while the glibenclamide blood levels differed by a factor of 1000, depending on the route of administration (Fig. 1) .
When measured at 1, 3, 5 and 10 rain after intragastric administration the lumen of the small intestine repeatedly contained 60% of the administered glibenclamide (Fig. 2) . The duodenal mucosa already containedmaximal glibenclamide concentrations (600 ng/g) after 1 min (Fig. 3) . This level remained constant when measured after 1, 3, 5 and 10 rain, respectively. Calculated from the concentration in the liver, the total drug absorption at the same time was estimated to be less than 0.5% of the minimal effective dose administered.
When 0.2 mg/kg glibenclamide was administered to fed rats intragastrically an immediate increase of DIRA was observed (Fig. 4) . The maximal concentration appeared in the mucosal material taken 30 seconds after intragastric administration.
The peak of insulin releasing activity (DIRA) preceded the rise in plasma IRI. The concentration of glibenclamide in mucosal extracts was always less than 0.2 ~tg/ml. When 0.5 ~tg/ml glibenclamide were added to extracts and injected into the coeliac trunk of the receptor rat, no additional effect was observed [32] .
Results of the study to characterize a possible direct insulinotropic effect of glibenclamide are shown in Figure 5 . Only in experiment E (fed donor rats, pretreated with glibenclamide, and glibenclamide added to donor rat plasma) could an increase in portal insulin of receptor rats be observed. Maximal IRI concentrations appreared 1 min after administration. Later the concentration fell, but remained significantly above that found in all other experiments.
Discussion
The pharmacokinetics and metabolism of glibenclamide in various animal species and man have been reported in previous papers [6, 16, 19, 27] . The kinetics of glibenclamide and serum IRI have been compared in dogs using i. v. injection and intragastric administration [16] . The results suggested that gastrointestinal mediators may be involved in the insulin releasing action of this drug. The more Blood of pretreated donor rats was collected 10 min after intragastric glibenclamide administration detailed data reported here support these previous findings. After intragastric administration a rapid accumulation of glibenclamide and an increase of DIRA in the mucosa correlate well with the rise in serum IRI. After about 20 min metabolites reach the intestinal tract via the bile. Therefore the pharmacokinetics of the drug cannot be calculated from tracer studies without making a correction for the metabolites.
A relatively high concentration of glibenclamide dissolved in plasma of fasted rats and injected into the coeliac trunk had no more effect on IRI levels than the plasma alone. This indicates that the plasma glibenclamide concentration used in this experiment has no direct effect on insulin release from the pancreas of the receptor rat. However, when the drug was added to plasma of rats pretreated with glibenclamide intragastrically, there was a significant elevation of IRI in the portal vein. In the plasma of pretreated rats a factor seems to be present which allows glibenclamide to have a direct effect on the pancreas.
The absence of an effect of glibenclamide dissolved in plasma of fasted or fed rats contradicts the well established direct action shown repeatedly by in vitro experiments [3, 12, 21, 22, 30] . Mariani [22] found that 1 ng glibenclamide/ml albumin containing medium is sufficient to release insulin from the perfused pancreas. Other authors, however, have reported much higher minimal effective drug concentrations: 250ng/ml [30] , 600ng/ml [21] , 2500 ng/ml [12] , and 8000 ng/ml [3] . According to these findings it seems likely that the concentrations used in the experiments reported here are too low to cause a direct effect of glibenclamide, except when compared with the data of Mariani [22] .
Furthermore it should be considered that the uptake of glibenclamide into the islets is decreased by protein binding (serum albumin) [15] . The protein binding of glibenclamide in rat serum exceeds 99% [13] . In our laboratory it was found that the binding of glibenclamide by serum albumins is less than 90%, with variation between different products and batches. Therefore the in vitro effect of the drug on IRI release from cultures of pancreatic cells could be observed in a protein free medium and in the presence of albumin, but not in the presence of complete serum [17] .
About 50 years ago Staub [28] and Traugott [29] observed that oral glucose increases the utilisation rate of a second oral glucose load. This has since been confirmed by Dupr6 [8] , Conard [7] , and Perley [23] . Recently Cerasi [4, 5] has found that in man intravenous glucose exerts two different effects, one which initiates the release of insulin and a second one which modulates the first action. The results reported here suggest to combine the assumption of a dual effect of glucose on insulin secretion with the findings of insulin release caused by a variety of gut factors. This combination may be interpreted as follows: after food and/or drugs such as glibenclamide by mouth, high concentrations of glucose, amino acids and drug appear in the gut. After intravenous administration of these components, the mucosal concentration may be also elevated via the circulation. The increasing concentrations of these substrates in the mucosal cells could cause the liberation of gut factor(s) which in their turn induce insufin release in the pancreas [10, 11, 31, 32, 33] . In the pancreas the gut factor(s) may amplify the direct insulinotropic action of the substrates. Under these experimental conditions neither the gut factor(s) nor glibenclamide alone could release insulin from the pancreas. This concept may explain the following observations on the kinetic pattern of IRI release in man: glucose [9, 20, 23] , amino acids [24] and sulfonylureas [16] are more effective in insulin release when given intragastrically or intraduodenally than intravenously. Within 2-5 min of intraduodenal glucose [26, 18] to man a high IRI output could be found in the portal blood, at a time when the portal blood glucose level was not increased. It is assumed that the gut factor may be released before the glucose has passed the intestinal wall. The IRI release after oral glucose in man [26] and after glibenclamide in dogs [16] follows a biphasic pattern. The first peak, seen very early, may be explained by the amplifying action of the gut factor in presence of a basal intracellular glucose concentration. The later peak may be caused by the gut factor together with increasing concentrations of substrates now being absorbed from the intestine. It has been shown repeatedly that a second glucose load regularly causes a higher IRI peak than the first one [4, 8] . This can be explained if one assumes that gut factor(s) released by the second load are superimposed on that of the first one, i. e. the amplifier is thought to have a relatively long half-life.
In an another paper we suggest that a similar mechanism may regulate the insulin release in man [32] .
In further studies we intend to investigate whether DIRA corresponds to one of the characterized intestinal gut factors and whether other sulfonylureas act in the same manner.
